A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. CellPryme-A acts ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX: PTX) CEO James McDonnell discusses the company’s ...

KRAS pathway activation in MPM from the cancer genome atlas (TCGA) pan‐cancer MPM dataset. A–F. Molecular and clinical features of the cancer genome atlas (TCGA) pan‐cancer MPM patients (n = 87) ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

The Ras-MAPK pathway was activated in both PBMC and kidney of patients with LN as indicated by increased expression of NRAS, KRAS, RIT1, MRAS, PPP1CB, SHOC2, SOS2 and MAP2K1, as well as decreased ...